[FOR RELEASE October 20, 2015 China Biologic Received Operating Permit for New Branch Collection Facility in Shandong Province BEIJING, China – October 20, 2015 – This new branch collection facility will operate under the Company’s Ningyang plasma collection station and cover the collection territory of Zaozhuang City, which has a population of 3.8 million and offers a reliable source of] []
[FOR RELEASE September 8, 2015 China Biologic to Build New Branch Collection Facility in Shandong Province BEIJING, China – September 8, 2015 – City, which has a population of 3.8 million and offers a reliable source of plasma donors. As the Company had This new plasma collection facility, located in Shanting District of Zaozhuang City, will be a branch of] []
[FOR RELEASE September 8, 2015 China Biologic to Build New Branch Collection Facility in Shandong Province BEIJING, China – September 8, 2015 – City, which has a population of 3.8 million and offers a reliable source of plasma donors. As the Company had This new plasma collection facility, located in Shanting District of Zaozhuang City, will be a branch of] []
[Strategic Cooperation Agreement to Source Raw Plasma This Agreement is entered on August 28, 2015 by and between: Party A Party B Party C WHEREAS 1. Party A has certain source plasma inventory for producing blood products. Party A has financial difficulty in keeping the daily operation of its plasma collections stations. 2. Party B has the need for source] [FOR RELEASE September 2, 2015 China Biologic Enters into Strategic Collaboration Agreement to Source Raw BEIJING, China – September 2, 2015 – The raw plasma will be shipped in batches to Guizhou Taibang for the production of human albumin and IVIG products. The Company expects that the products made from the sourced raw plasma will begin to reach the market] []
[Strategic Cooperation Agreement to Source Raw Plasma This Agreement is entered on August 28, 2015 by and between: Party A Party B Party C WHEREAS 1. Party A has certain source plasma inventory for producing blood products. Party A has financial difficulty in keeping the daily operation of its plasma collections stations. 2. Party B has the need for source] [FOR RELEASE September 2, 2015 China Biologic Enters into Strategic Collaboration Agreement to Source Raw BEIJING, China – September 2, 2015 – The raw plasma will be shipped in batches to Guizhou Taibang for the production of human albumin and IVIG products. The Company expects that the products made from the sourced raw plasma will begin to reach the market] []
[China Biologic Products, Inc. 8th Floor, Jialong International Building 19 Chaoyang Park Road Chaoyang District, Beijing 100125 People’s Republic of China August 5, 2015 VIA EDGAR 100 F Street, N.E. Re: Notice of Disclosure Filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the]
[] [CERTIFICATIONS I, David (Xiaoying) Gao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Ming Yang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [OF THE SARBANES-OXLEY ACT OF 2002 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th David (Xiaoying) Gao Chief Executive Officer] [OF THE SARBANES-OXLEY ACT OF 2002 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th Ming Yang Chief Financial Officer (Principal Financial Officer)]
[] [CERTIFICATIONS I, David (Xiaoying) Gao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Ming Yang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [OF THE SARBANES-OXLEY ACT OF 2002 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th David (Xiaoying) Gao Chief Executive Officer] [OF THE SARBANES-OXLEY ACT OF 2002 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th Ming Yang Chief Financial Officer (Principal Financial Officer)]
[August 5, 2015 100 F Street, N.E. Ladies and Gentlemen: We were previously independent registered public accounting firm for China Biologic Products, Inc. (“the Company”) and, under the date of March 4, 2015, we reported on the consolidated financial statements of the Company as of and for the years ended December 31, 2014 and 2013, and the effectiveness of internal] [FOR RELEASE August 5, 2015 China Biologic Reports Financial Results for the Second Quarter of 2015 2Q15 Total Sales Increased 31.6% YoY to $79.1 Million 2Q15 Non-GAAP Net Income Increased 39.5% YoY to $28.6 Million 1H15 Total Sales Increased 28.5% YoY to $149.4 Million 1H15 Non-GAAP Net Income Increased 35.1% YoY to $53.5 Million BEIJING, China – August 5, 2015] []
[August 5, 2015 100 F Street, N.E. Ladies and Gentlemen: We were previously independent registered public accounting firm for China Biologic Products, Inc. (“the Company”) and, under the date of March 4, 2015, we reported on the consolidated financial statements of the Company as of and for the years ended December 31, 2014 and 2013, and the effectiveness of internal] [FOR RELEASE August 5, 2015 China Biologic Reports Financial Results for the Second Quarter of 2015 2Q15 Total Sales Increased 31.6% YoY to $79.1 Million 2Q15 Non-GAAP Net Income Increased 39.5% YoY to $28.6 Million 1H15 Total Sales Increased 28.5% YoY to $149.4 Million 1H15 Non-GAAP Net Income Increased 35.1% YoY to $53.5 Million BEIJING, China – August 5, 2015] []
